Compare Capital One Financial Corp. (COF) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs Twist Bioscience Corp — how do they compare? Capital One Financial Corp. trades at $219.75 (market cap $134.33B), while Twist Bioscience Corp trades at $123.01 (market cap $7.82B). The key difference: Capital One Financial Corp. is far larger — about 17.2× Twist Bioscience Corp's market cap, and Capital One Financial Corp. pays a 1.46% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| COF | TWST | |
|---|---|---|
Market Cap | $134.33B | $7.82B |
Sector | Financials | Health |
52-Week High | $257.94 | $124.88 |
52-Week Low | $176.10 | $24.16 |
Dividend Yield | 1.46% | — |
Enterprise Value | — | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $217.76, down 1.02% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81 versus $4.79 expected, driven by strong revenue growth and integration progress with Discover Financial. The stock shows a P/E of 12 and net income margin of 16.96%, reflecting solid valuation and profitability metrics amid ongoing business expansion.
The outlook for COF is positive, supported by earnings momentum, synergy capture from the Discover acquisition, and analyst optimism. Key risks include integration execution, credit loss provisions, and macroeconomic pressures on consumer lending. With 63% of analysts rating it a buy, the stock presents a growth opportunity tempered by sector-specific challenges.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
